Beur schreef op 15 maart 2016 19:46:
Het gaat helemaal nie goe met Valeant ...:
Valeant struggling to stay ahead of creditors given ongoing filing delay"Valeant Pharmaceuticals International still hasn’t filed its annual report with the Securities and Exchange Commission and that means the company is squeezed between creditors who can force early repayment of debt for not meeting terms of their loans and investors who want it to get back to business as usual.
"Tom Selling, author of the blog Accounting Onion, told MarketWatch that unless Valeant reaches an agreement soon with its creditors “that forestalls an accelerated debt repayment scenario, PwC will be under pressure to consider including going concern language in its audit report.”
A going concern warning from auditor PwC could also potentially cause a breach of covenants in any debt agreement that requires a clean audit report with no qualifications."
"Edward Ketz, a professor of accounting at Penn State University, says Valeant has two choices for generating enough cash to pay its outstanding debt. “The firm can issue more debt or sell valuable assets,” said Ketz. “Issuing additional debt will be very expensive. Selling valuable assets will take time and it will hurt future revenue prospects.”
Dat wordt op zijn minst grof bezuinigen. Toch niet op Het Ruc/profylactisch programma samen met Pharming....?
www.marketwatch.com/story/valeant-str...